机构:[1]Department of Gynecology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, China[2]Department of Oncology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, China[3]Department of Oncology, The Second Affiliated Hospital Of Xingtai Medical College, Xingtai, China[4]Department of Oncology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China临床科室肿瘤内科河北医科大学第四医院[5]Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, China
IntroductionIt is believed that ovarian cancer (OC) is the most deadly form of gynecological cancer despite its infrequent occurrence, which makes it one of the most salient public health concerns. Clinical and preclinical studies have revealed that intratumoral CD4+ T cells possess cytotoxic capabilities and were capable of directly killing cancer cells. This study aimed to identify the CD4+ conventional T cells-related genes (CD4TGs) with respect to the prognosis in OC. MethodsWe obtained the transcriptome and clinical data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. CD4TGs were first identified from single-cell datasets, then univariate Cox regression was used to screen prognosis-related genes, LASSO was conducted to remove genes with coefficient zero, and multivariate Cox regression was used to calculate riskscore and to construct the CD4TGs risk signature. Kaplan-Meier analysis, univariate Cox regression, multivariate Cox regression, time-dependent receiver operating characteristics (ROC), decision curve analysis (DCA), nomogram, and calibration were made to verify and evaluate the risk signature. Gene set enrichment analyses (GSEA) in risk groups were conducted to explore the tightly correlated pathways with the risk group. The role of riskscore has been further explored in the tumor microenvironment (TME), immunotherapy, and chemotherapy. A risk signature with 11 CD4TGs in OC was finally established in the TCGA database and furtherly validated in several GEO cohorts. ResultsHigh riskscore was significantly associated with a poorer prognosis and proven to be an independent prognostic biomarker by multivariate Cox regression. The 1-, 3-, and 5-year ROC values, DCA curve, nomogram, and calibration results confirmed the excellent prediction power of this model. Compared with the reported risk models, our model showed better performance. The patients were grouped into high-risk and low-risk subgroups according to the riskscore by the median value. The low-risk group patients tended to exhibit a higher immune infiltration, immune-related gene expression and were more sensitive to immunotherapy and chemotherapy. DiscussionCollectively, our findings of the prognostic value of CD4TGs in prognosis and immune response, provided valuable insights into the molecular mechanisms and clinical management of OC.
基金:
innovation ability improvement plan project of Xingtai City [2022zz091]
第一作者机构:[1]Department of Gynecology, Affiliated Xingtai People Hospital of Hebei Medical University, Xingtai, China
通讯作者:
通讯机构:[4]Department of Oncology, Hebei Medical University, Fourth Hospital, Shijiazhuang, China[5]Hebei Key Laboratory of Precision Diagnosis and Comprehensive Treatment of Gastric Cancer, Shijiazhuang, China
推荐引用方式(GB/T 7714):
Hua Tian,Liu Deng-xiang,Zhang Xiao-chong,et al.CD4+conventional T cells-related genes signature is a prognostic indicator for ovarian cancer[J].FRONTIERS IN IMMUNOLOGY.2023,14:doi:10.3389/fimmu.2023.1151109.
APA:
Hua, Tian,Liu, Deng-xiang,Zhang, Xiao-chong,Li, Shao-teng,Yan, Peng...&Chen, Shu-bo.(2023).CD4+conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.FRONTIERS IN IMMUNOLOGY,14,
MLA:
Hua, Tian,et al."CD4+conventional T cells-related genes signature is a prognostic indicator for ovarian cancer".FRONTIERS IN IMMUNOLOGY 14.(2023)